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Abstract
Molecule-targeted therapies are being widely developed and deployed, but they are frequently less effective in clinical trials
than predicted based upon preclinical studies. Frequently, only a single model or genetic background is utilized using diets
that are not relevant to that consumed by most cancer patients, which may contribute to the lack of predictability of many
preclinical therapeutic studies. Inhibition of epidermal growth factor receptor (EGFR) in colorectal cancer was used to
investigate potential causes for low predictive values of many preclinical studies. The efficacy of the small molecule EGFR
inhibitor AG1478 was evaluated using two mouse models, Apc
Min/+ and azoxymethane (AOM), both sexes on three genetic
backgrounds, C57BL/6J (B6) and A/J (A) inbred strains and AB6F1 hybrids, and two diets, standard chow (STD) or Western-
style diet (WD). AG1478 has significant anti-tumor activity in the B6-Apc
Min/+ model with STD but only moderately on the
WD and in the AOM model on an A background with a WD but not STD. On the F1 hybrid background AG1478 is effective in
the Apc
Min/+ model with either STD or WD, but has only moderate efficacy in the AOM model with either diet. Sex
differences were also observed. Unexpectedly, the level of liver EGFR phosphorylation inhibition by AG1478 was not
positively correlated with inhibition of tumor growth in the AOM model. Model-dependent interactions between genetic
background and diet can dramatically impact preclinical results, and indicate that low predictive values of preclinical studies
can be attributed to study designs that do not account for the heterogeneous patient population or the diets they
consume. Better-designed preclinical studies should lead to more accurate predictions of therapeutic response in the clinic.
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Introduction
While many new promising therapies are being approved for
cancer treatment, it is becoming clear that their efficacy in clinical
trials is not reflective of that predicted in preclinical studies. An
analysis of published Phase 1 clinical trials from 1991–2002
revealed that only 3.8% of patients showed a significant clinical
response [1]. Animal models used in preclinical studies to guide
clinical trials have been useful in predicting targets and elucidating
their mechanisms of action, but these models are rarely designed
to incorporate heterogeneous factors faced in human clinical trials,
such as genetics and diet, which likely contribute to the
inconsistencies observed when moving a drug from preclinical to
clinical status.
Among the most prevalent cancers, colorectal cancer (CRC) has
the lowest Phase I response rate at 1.3% [1], necessitating an
investigation into how preclinical studies can be improved. A
target of significant interest over the last ten years, often touted as
the prototype for molecule-targeted therapies [2], is the epidermal
growth factor receptor (EGFR) whose signaling is deregulated in
up to 50% of CRCs [3]. Numerous therapeutic agents have been
developed to target EGFR with the hope that they would be
potent CRC therapeutics. These therapies include small molecule
inhibitors that target the kinase domain and blocking antibodies
against the ligand-binding domain.
Mouse models developed to study the etiology of CRC are
frequently used in preclinical studies. The most widely used
models are the Apc
Min/+ and azoxymethane (AOM)-treated mouse
models [4–7]. Previous studies have shown that Apc
Min/+ tumors
display increased EGFR activity, and that treatment with small
molecule EGFR inhibitors results in a significant decrease in
tumor incidence in these mice [8–10]. In addition, though
preclinical studies have yet to report efficacy of EGFR-inhibition
in the AOM model, AOM-induced tumors show increased EGFR
activity [11,12], therefore it is reasonable to hypothesize that this
model will also respond to EGFR-targeted treatment. Although
many preclinical studies have provided evidence for the potential
efficacy of EGFR-targeted treatment of CRC, these studies have
not accurately predicted the poor response observed in the clinic.
One possible issue with preclinical trials is the oversimplification of
modeling human trials in mice.
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5Diet is rarely considered in the design of preclinical therapeutic
studies. For example, Western-style diets commonly consumed in
North America and Europe are characterized by high levels of fat
and low amounts of fruits and vegetables, factors not considered
when performing preclinical studies. Studies have linked Western-
style diets to increased cancer incidence, including CRC.
Modeling the Western-style diet in mice, with increased fat,
decreased Vitamin D, and decreased calcium, results in increased
hyperproliferation in pancreatic, prostate and mammary epithelial
cells [13]. The same diet induces hyperproliferation in intestinal
epithelial cells of wild-type C57BL/6 (B6) mice [14]. Further
modification of the diet to include decreased levels of folate and
other nutrients essential for DNA methylation induces adenomas
and carcinomas in mice [14,15].
In addition to the potential for diet to influence tumorigenesis, it
is also evident that genetic background is important. As with
human CRC, susceptibility to AOM-induced tumors is dependent
on genetic background [16–18]. A/J (A) mice, for example, are
highly susceptible to AOM-induced colon tumors whereas B6
mice are relatively resistant. Likewise, tumor incidence in the
Apc
Min/+ model is greatly dependent on mouse strain, with B6 mice
bearing significantly more tumors compared to F1 mice with less
susceptible strains like AKR/J and A [19,20].
With the knowledge that genetic background and diet
differentially influence tumor incidence, it is reasonable to expect,
albeit not yet tested, that they may also be important factors
contributing to the variability of EGFR-targeted therapies. To
determine the importance of experimental conditions on pre-
clinical studies, we investigated the efficacy of the small molecule
EGFR inhibitor AG1478 using different mouse models, diets and
genetic backgrounds.
Materials and Methods
Ethics Statement
All experiments were approved by the UNC Institutional
Animal Care and Use Committee (protocol #07-069.0).
Experimental Design
Equal numbers of male and female inbred strain ‘‘A’’ mice were
obtained from The Jackson Laboratory and maintained on 5058
mouse chow (LabDiet). Additionally, A X C57BL/6 F1 (AB6F1)
hybrid mice were generated in house. At four months of age mice
were injected weekly with AOM (10 mg/kg body weight) for six
weeks (Figure 1). One week prior to the first AOM injection, mice
were moved to a standard diet (STD; AIN-93G from Research
Diets), then one week after the last AOM injection, mice were
randomly assigned to one of two diets, STD or Western (WD;
D12079B from Research Diets) (Table 1), with or without
144 mg/kg chow of EGFR-inhibitor AG1478 (LC Labs). WD is
nutritionally matched with the STD except for increased fat and
reduced fiber, calcium and vitamin D, more consistent with the
diets consumed by people in North America. Mice were
maintained on their respective diet for 12 weeks before being
euthanized with CO2. Colons were dissected, flushed with
phosphate-buffered saline (PBS), splayed on bibulous paper and
scored for tumor number, diameter and location (in mm from
distal end).
Wild-type C57BL/6 (‘‘B6’’) and A females were also mated to
B6-Apc
Min/+ males to generate B6-Apc
Min/+ inbred and AB6F1-
Apc
Min/+ hybrids, respectively, and progeny containing the Apc
Min
allele were weaned at 3 weeks of age and assigned to STD or WD,
with or without AG1478 (Figure 1). After 9 weeks of treatment
mice were euthanized and the entire intestinal tract was flushed
with PBS and splayed on bibulous paper. The intestine was
divided into 4 sections: small intestine (duodenum, jejunum, and
ileum) and colon.
General health of the mice was monitored by appearance
(mobility and ability to groom) and body weights measured
biweekly for the AOM model and weekly for the Apc
Min/+ model
(data not shown as only genetic-background and diet, but not
treatment or model, affected body weight). All mice were housed
in an AAALAC approved-facility and provided chow and water ad
libitum. Mice were kept specific pathogen free.
Western Blot Analysis for EGFR Signal
Five minutes prior to euthanasia mice were injected with 10 ml/
g body weight of 5 mM phosphatase inhibitor sodium orthova-
nadate (activated with 50 mM hydrogen peroxide 15 minutes
prior to use) [21]. After euthanasia, livers were dissected and snap
frozen in liquid nitrogen. Total protein was extracted with lysis
buffer containing 10 mM Tris-HCl (pH 8), 100 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM NaF, 1% NP-40, 10% Glycerol,
0.1% SDS, 0.5% Sodium deoxycholate, 1 mM PMSF, 10 mg/ml
leupeptin, 10 mg/ml aprotinin, 1 mM Na3VO4, and 1 mM NaF.
A Bradford protein assay was used to determine protein
concentration (Bio-Rad).
Thirty mg of liver protein was loaded onto 4–15% gradient Tris-
HCl gels (Bio-Rad). After transfer to PVDF membranes for one
hour, membranes were blocked for one hour in 5% BSA/TBS
(0.1% Tween) for rabbit anti-pEGFR 1068 antibody (Cell
Signaling) or 5% milk/TBST for sheep anti-EGFR (Millipore)
and mouse anti-ACTB (Sigma) antibodies. Membranes were
incubated with primary antibody overnight at 4uC. Antibodies
against pEGFR were diluted 1:2,000 in 1% BSA/TBST, EGFR
diluted 1:5,000 and ACTB diluted 1:10,000 in 5% milk/TBST.
After washing, membranes were incubated with secondary
antibodies for one hour at room temperature. Secondary
antibodies (Jackson ImmunoResearch) were diluted 1:20,000 in
the same solution as the primary antibody. SuperSignal West Dura
Extended Duration ECL (Pierce) was used for visualization of
proteins. A minimum of 4 replicates (2 per sex) were performed
per treatment and model/strain.
Statistical Analysis
Summary Table 2 was constructed using p-values from Mann-
Whitney analysis (Prism 4.0 (GraphPad Software, Inc.)) of all
possible pair-wise comparisons within each model/strain and
treatment for association with tumor number or size (dependent
variables). Sex was not a factor in this summary analysis. For
Apc
Min/+ mice, p-values were corrected for 12 comparisons and p-
values for AOM mice were corrected for 6 (half as many because
tumors only occurred in the colon in this model). This analysis was
done for tumor number and tumor size separately. Down arrows
in the table indicate a corrected p-value of ,0.05, while ‘‘trend’’
indicates an uncorrected p-value of ,0.05 that rises above 0.05
after correction.
Linear mixed models (SPSS v. 20) were performed separately
for the Apc
Min/+ and AOM CRC mouse models to assess the
impact of diet (STD vs WD), AG1478 treatment (‘‘2‘‘ no
treatment vs ‘‘+’’ treatment), and sex on tumor number and size.
Models were evaluated using mouse strain (B6 vs F1 for Apc
Min/+
and A vs F for AOM mice) as a random effect and diet, AG1478
and sex as fixed effects. Tests of all possible interactions between
the fixed effects were also evaluated. Dependent variables were
tumor number or tumor size. For the Apc
Min/+ model, small
intestinal and colonic tumors were evaluated separately.
Preclinical EGFR Therapy Testing
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(rsbweb.nih.gov/ij/) was used to estimate the density of the bands
on the western blots. For each individual blot, EGFR and pEGFR
bands were normalized to the loading control (b-actin) that was
run in the same lane. pEGFR was then calculated as a percentage
of total EGFR for each lane. Finally, all treatments (STD/
+AG1478, WD/2AG1478 and WD/+AG1478) were normalized
to untreated (STD/2AG1478) for each blot. Mouse models/
strains and sex were run on separate blots. A minimum of 4
replicates (2 per sex) were run per treatment and model/strain.
Linear mixed models were performed to assess the association of
diet, sex, AG1478 (fixed effects) and strain (random effect) with
pEGFR signal. The dependent variable was the normalized
pEGFR signal. Bar graphs were constructed using Prism 4.0
(GraphPad Software, Inc.).
Results
Western-style Diet Increases Tumor Growth in Apc
Min/+
Mice
Consistent with previous reports, WD is associated with
increased tumor number compared to a STD in Apc
Min/+ mice
(Figure 2A; p,0.001 in small intestine and p=0.090 in colon).
WD was also moderately associated with increased size of small
intestinal tumors in the Apc
Min/+ model (Figure 3A; p=0.073). WD
was not, however, associated with a change in tumor number or
size in the AOM mouse model.
Efficacy of EGFR Inhibition on Tumor Growth is Variable
Across Diet, Model, Sex and Strain
Evaluation of the efficacy of EGFR inhibition on tumor growth
showed variable results dependent on diet, model and genetic
background. Table 2 showsgeneralpair-wise observationsof tumor
numberandsizeforeachCRCmousemodel,Apc
Min/+andAOM.In
addition to differential response observed between mouse models,
we observe differences in response EGFR inhibitor AG1478 within
each model according to strain (inbred vs F1). Apc
Min/+ mice on the
F1 genetic background had the most favorable overall response to
AG1478withadecreaseintumornumberandsizeonboththeSTD
and WD diets. On the other hand, AOM mice on the F1 genetic
background had the least favorable response to AG1478 with no
Figure 1. Experimental design. At weaning (Apc
Min/+) or 1 week following the last carcinogen treatment (AOM) mice were randomly assigned to
a Standard (STD) or Western-style (WD) base diet, with or without small-molecule EGFR inhibitor AG1478. The total number of mice per model/strain
(N) is displayed in the table below the diagram with the number of females in parentheses.
doi:10.1371/journal.pone.0039552.g001
Table 1. Comparison of diet compositions.
Standard Diet Western Diet
Calories (kcal/g) 4 4.7
Fat (kcal%) 16 41
Fat type Soybean oil Milk, corn oil
Carbohydrates (kcal%) 64 43
Sucrose (kcal%) 10 29
Protein (kcal%) 20 17
Cholesterol (%) 0 0.21
Fiber (%) 52
Calcium (g/kg) 5 0.5
Vitamin D (IU/kg) 1000 100
doi:10.1371/journal.pone.0039552.t001
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‘‘trends’’ towards significance were observed for some of the
models/strains as the pair-wise p-value rose above 0.05 after
correction for multiple comparisons.
Linear mixed model results for tumor number (Figure 2) and
tumor size (Figure 3) in the Apc
Min/+ and AOM models provide
a more detailed assessment of the affect of diet, strain and sex on
EGFR inhibition of tumor growth. Using strain as the random
effect, we confirm previous reports [8–10] that pharmacologic
inhibition of EGFR decreases small intestinal tumor number and
size in the Apc
Min/+ mice (Figure 2A, p=0.003 and Figure 3A,
p,0.001, respectively). AG1478 is also associated with decreased
colonic tumor number (Figure 2A, p,0.001). An interaction
between AG1478 treatment and diet for this model, while
controlling for strain, is observed in association with colonic
tumor number and size (p=0.003 and p=0.010, respectively).
AG1478 treatment was also associated with decreased colonic
tumor number in AOM mice (small intestinal tumors are not
observed in this mouse model) (Figure 2B, p=0.004). Similar to
the Apc
Min/+ mice, AG1478 treatment and diet interact to impact
colonic tumor number (but not size) in AOM mice (p=0.037).
In addition to diet and AG1478 treatment, sex was included as
a fixed effect when assessing tumor number and size in each model
(with strain as the random effect). AOM females have a higher
incidence of colonic tumors (Figure 2B, p,0.001). Additionally,
Apc
Min/+ females have larger small intestinal and colonic tumors
compared to males (Figure 3A, p=0.031 and p=0.057, re-
spectively). An interaction between sex and AG1478 treatment is
observed in association with colonic tumor number in Apc
Min/+
(Figure 2A, p=0.001) and moderately with AOM tumor size
(Figure 3B, p=0.080). An interaction between all fixed effects
(diet, strain and AG1478) is observed in association with colonic
tumor number in Apc
Min/+ mice (Figure 2A, p=0.008). Finally, sex
and diet interact in association to affect small intestinal tumor size
in Apc
Min/+ mice (Figure 3A, p=0.030).
Impact of AG1478 on EGFR Signaling is Dependent on
Mouse Model and Diet
To evaluate the level of EGFR inhibition achieved by AG1478
under different experimental conditions, reduction in phosphor-
ylated EGFR (pEGFR) was measured in liver lysates; there was
insufficient material to directly measure levels in tumors. Analyses
were performed by sex since sex-dependent effects were observed
in the tumor growth analyses (Figures 2 and 3). Signal intensities
were normalized to a loading control run in the same lane.
pEGFR/EGFR was calculated for each lane and the pEGFR/
EGFR ratios for STD/+AG1478, WD/2AG1478 and WD/
+AG1478 were normalized to the STD untreated (no AG1478)
pEGFR/EGFR ratio on the corresponding gel. This normalized
ratio, ‘‘pEGFR signal’’, was used as the dependent variable in
subsequent linear mixed models.
For Apc
Min/+ mouse liver lysates linear mixed model results show
that AG1478 is moderately associated with decreased pEGFR
signal (Figure 4A, p=0.061). Conversely, AG1478 alone does not
affect pEGFR signal in AOM mouse liver lysates. However, when
combined with diet AG1478 treatment is associated with increased
pEGFR signal (Figure 4B, p=0.042). STD alone is also associated
with increased pEGFR signal compared to WD in AOM mice
(Figure 4B, p=0.024).
Discussion
Designing preclinical studies for cancer therapeutics that more
closely model conditions faced in human clinical trials is essential
to improve predictions of drug efficacy. In the current study we
investigated the efficacy of the small molecule EGFR inhibitor
AG1478 for treatment of CRC using two mouse models, each on
a distinct inbred strain and a common F1 genetic background to
model genetic heterogeneity of the CRC patient population.
Additionally, a standard mouse diet similar to that used in most
preclinical studies was compared to the impact of modeling
a Western-style diet on efficacy of EGFR inhibitor therapy.
We observed a different, sometimes dramatic, response to
AG1478 for each of the four combinations of model and genetic
background. Within the inbred strains, AG1478 significantly
inhibits tumor number when combined with the STD in the B6-
Apc
Min/+model orwiththe WDinAmice treatedwithAOM.Inthe
AB6F1 background, AG1478 reduces tumor number on both diets
in the Apc
Min/+ model, but has little impact on tumor number on
either diet in the AOM model, only trending towards an effect on
STD. Whether using an inbred or F1 hybrid background, we
essentially observed opposing results between the two models. In
some cases where tumor number reduction was not observed,
reduction in tumor size was observed suggesting that EGFR
inhibition does have some efficacy even when tumor number is
unaffected.
We also observed a differential response to diet alone. WD
increased tumor number and size in some mice. Studies have
shown that the EGFR pathway is influenced by many diet-related
factors, including dietary and herbal supplements [22] and fatty
acids [23,24]. Unsaturated fatty acids activate EGFR signaling in
a rodent model of breast cancer as well as human endothelial cells.
In the rodent model, a diet high in polyunsaturated fat (corn oil)
increased phospho-EGFR signal while monounsaturated fat (olive
oil) decreased signal. In endothelial cells unsaturated fat in the
form of oleic acid and polyunsaturated fatty acids induced EGFR
activity and downstream MAPK activation, possibly through
direct interaction with the receptor, and this induction depended
on degree of saturation.
Table 2. Summary of pair-wise observations of AG1478 inhibitor effect on tumor growth.
SD SD WD WD
Strain Model Tumor Number Tumor Size Tumor Number Tumor Size
B6 Apc
Min/+ Q – trend Q
ABF1 Apc
Min/+ QQ Q Q
A AOM – trend – –
ABF1 AOM trend – – –
SD standard diet; WD, western diet; Q corrected p,0.05; trend, uncorrected p,0.05 but corrected p.0.05.
doi:10.1371/journal.pone.0039552.t002
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account for the contradictory response to AG1478 other factors
should be considered. The B6-Apc
Min/+ and AOM-treated A mouse
models also have differential susceptibility to diet-induced obesity
withtheB6backgroundbeingsusceptible,whiletheAbackgroundis
resistant. Furthermore, the distribution of tumors (entire intestinal
tractversuscolononly),ageatonsetofdiettreatment(3weeksversus
6 months), length of diet treatment (9 versus 12 weeks), initiating
mutationalevents(ApcversusCtnnb1)andpotentiallymicrofloramay
also contribute to model-dependent differences in response to
AG1478. Since mice of the same model/strain were maintained
within the same room we do not expect a significance difference in
microflora within these groups but differences between the groups
cannot be ruled out. Each of these differences, particularly
susceptibility to obesity, distribution of tumors and microflora,
likely contribute to strain and model differences in metabolism of
dietary and therapeutic agents.
Finally, sex-dependent influences on tumor incidence and
tumor response to both diet and AG1478 treatment exist. Overall
tumor number was higher in AOM-treated female mice on A and
AB6F1 backgrounds. In addition, only females were vulnerable to
WD-induced tumors in the AOM model (data not shown). For this
Figure 2. Effect of diet, sex and strain on AG1478-mediated tumor number reduction. A) Apc
Min/+ small intestinal and colonic tumor
number as a percentage of STD without AG1478 treatment for the B6 inbred and AB6F1 (shaded) strains; and B) AOM (A and AB6F1) colonic tumor
number expressed as a percent of STD treatment. The raw values for average number of tumors/mouse are displayed below each graph.
STD=standard diet, WD=western diet, ‘‘+’’ = AG1478 treatment and ‘‘2‘‘ = no AG1478 treatment. Standard Error of the Mean bars are shown for
each treatment. Below bar graphs are estimated effects and significance based on linear mixed models.
doi:10.1371/journal.pone.0039552.g002
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according to sex in addition to model and strain.
In liver the impact of AG1478 on EGFR signaling is variable
depending on model and diet. AG1478 is associated with
decreased pEGFR signal in Apc
Min/+mice. This is in agreement
with the overall greater affect of AG1478 towards inhibiting tumor
growth in this model. In AOM mice, though, diet is more strongly
associated with pEGFR signal and AG1478 only affects pEGFR
signal when combined with diet in the linear model.
Circumstances where AG1478 reduces EGFR signal but not
tumor growth may indicate the presence of EGFR-independent
tumors. We also must consider that, while AG1478 is metabolized
in the liver, EGFR signaling in liver may not always reflect an
equivalent impact on EGFR signaling in tumors. Additionally,
dietary components or crosstalk with other pathways may interfere
with AG1478 efficacy or our ability to observe its impact on
signaling. Finally, we may be limited by the number of replicates,
and closer observation of downstream signaling may be required.
Results for AG1478, which models a typical preclinical
therapeutic study, demonstrates that better experimental designs
are essential to improve the value of preclinical studies for
predicting future clinical utility of new cancer therapeutics. We
therefore propose that genetic background, sex, diet, and disease
model be considered in future preclinical cancer studies. While
initially these improvements may be more costly and time
consuming, ultimately they will greatly reduce time and expense
by more accurately informing human clinical trials.
Figure 3. Effect of diet, sex and strain on AG1478-mediated tumor size(mm) reduction. A) Apc
Min/+ small intestinal and colonic tumor size
as a percentage of STD without AG1478 treatment for the B6 inbred and AB6F1 (shaded) strains; and B) AOM (A and AB6F1) colonic tumor size
expressed as a percent of STD treatment. The raw values for average size of tumors/mouse are displayed below each graph. STD=standard diet,
WD=western diet, ‘‘+’’ = AG1478 treatment and ‘‘2‘‘ = no AG1478 treatment. Standard Error of the Mean bars are shown for each treatment. Below
bar graphs are estimated effects and significance based on linear mixed models.
doi:10.1371/journal.pone.0039552.g003
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